Adenosine receptors as drug targets—what are the challenges?

JF Chen, HK Eltzschig, BB Fredholm - Nature reviews Drug discovery, 2013 - nature.com
Adenosine signalling has long been a target for drug development, with adenosine itself or
its derivatives being used clinically since the 1940s. In addition, methylxanthines such as …

Astrocytes as guardians of neuronal excitability: mechanisms underlying epileptogenesis

QP Verhoog, L Holtman, E Aronica… - Frontiers in …, 2020 - frontiersin.org
Astrocytes are key homeostatic regulators in the central nervous system and play important
roles in physiology. After brain damage caused by eg, status epilepticus, traumatic brain …

Molecular mechanisms and potential therapeutical targets in Huntington's disease

C Zuccato, M Valenza, E Cattaneo - Physiological reviews, 2010 - journals.physiology.org
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat
expansion in the gene encoding for huntingtin protein. A lot has been learned about this …

Caffeine and adenosine

JA Ribeiro, AM Sebastiao - Journal of Alzheimer's disease, 2010 - content.iospress.com
Caffeine causes most of its biological effects via antagonizing all types of adenosine
receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons …

Caffeine and anaerobic performance: ergogenic value and mechanisms of action

JK Davis, JM Green - Sports medicine, 2009 - Springer
The effect caffeine elicits on endurance performance is well founded. However,
comparatively less research has been conducted on the ergogenic potential of anaerobic …

Focusing on adenosine receptors as a potential targeted therapy in human diseases

WI Effendi, T Nagano, K Kobayashi, Y Nishimura - Cells, 2020 - mdpi.com
Adenosine is involved in a range of physiological and pathological effects through
membrane-bound receptors linked to G proteins. There are four subtypes of adenosine …

Purinergic signalling: from normal behaviour to pathological brain function

G Burnstock, U Krügel, MP Abbracchio, P Illes - Progress in neurobiology, 2011 - Elsevier
Purinergic neurotransmission, involving release of ATP as an efferent neurotransmitter was
first proposed in 1972. Later, ATP was recognised as a cotransmitter in peripheral nerves …

Purinergic signalling and disorders of the central nervous system

G Burnstock - Nature reviews Drug discovery, 2008 - nature.com
Purines have key roles in neurotransmission and neuromodulation, with their effects being
mediated by the purine and pyrimidine receptor subfamilies, P1, P2X and P2Y. Recently …

[HTML][HTML] Adenosine receptors and brain diseases: neuroprotection and neurodegeneration

CV Gomes, MP Kaster, AR Tomé, PM Agostinho… - … et Biophysica Acta (BBA …, 2011 - Elsevier
Adenosine acts in parallel as a neuromodulator and as a homeostatic modulator in the
central nervous system. Its neuromodulatory role relies on a balanced activation of inhibitory …

Adenosine A2A receptor mediates microglial process retraction

AG Orr, AL Orr, XJ Li, RE Gross, SF Traynelis - Nature neuroscience, 2009 - nature.com
Cell motility drives many biological processes, including immune responses and embryonic
development. In the brain, microglia are immune cells that survey and scavenge brain tissue …